DK3406717T3 - Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter - Google Patents

Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter Download PDF

Info

Publication number
DK3406717T3
DK3406717T3 DK18183032.4T DK18183032T DK3406717T3 DK 3406717 T3 DK3406717 T3 DK 3406717T3 DK 18183032 T DK18183032 T DK 18183032T DK 3406717 T3 DK3406717 T3 DK 3406717T3
Authority
DK
Denmark
Prior art keywords
antibody
expression
development
same time
protein performance
Prior art date
Application number
DK18183032.4T
Other languages
English (en)
Inventor
Jay Milton Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Application granted granted Critical
Publication of DK3406717T3 publication Critical patent/DK3406717T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
DK18183032.4T 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter DK3406717T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
EP16196481.2A EP3156485B1 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Publications (1)

Publication Number Publication Date
DK3406717T3 true DK3406717T3 (da) 2020-03-16

Family

ID=43450243

Family Applications (5)

Application Number Title Priority Date Filing Date
DK19210622.7T DK3636759T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter
DK16196481.2T DK3156485T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter
DK18183032.4T DK3406717T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter
DK16157965.1T DK3042957T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af human protein-ydelse og ekspression i produktionsværter
DK15156820.1T DK2907873T3 (da) 2009-07-17 2010-07-16 Samtidig integreret udvælgelse og udvikling af antistof-/protein-ydelse og deres eksprimering i produktionsværter

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK19210622.7T DK3636759T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter
DK16196481.2T DK3156485T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK16157965.1T DK3042957T3 (da) 2009-07-17 2010-07-16 Samtidig, integreret udvælgelse og udvikling af human protein-ydelse og ekspression i produktionsværter
DK15156820.1T DK2907873T3 (da) 2009-07-17 2010-07-16 Samtidig integreret udvælgelse og udvikling af antistof-/protein-ydelse og deres eksprimering i produktionsværter

Country Status (19)

Country Link
US (5) US8859467B2 (da)
EP (6) EP3636759B1 (da)
JP (3) JP6193570B2 (da)
KR (5) KR20190017070A (da)
CN (2) CN102625848A (da)
AU (5) AU2010273974B2 (da)
BR (2) BR112012001171B1 (da)
CA (2) CA3034484A1 (da)
DK (5) DK3636759T3 (da)
ES (3) ES2701931T3 (da)
HK (1) HK1210623A1 (da)
HU (1) HUE029328T2 (da)
IN (1) IN2012DN00737A (da)
MX (2) MX347654B (da)
MY (2) MY160472A (da)
PL (2) PL3042957T3 (da)
PT (1) PT3042957T (da)
SG (3) SG177687A1 (da)
WO (1) WO2011009058A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636759B1 (en) 2009-07-17 2023-10-11 BioAtla, Inc. Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
EP2593797B1 (en) 2010-07-16 2019-05-08 Bioatla, LLC Novel methods of protein evolution
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
US20140302999A1 (en) * 2011-11-03 2014-10-09 Magdalena Leszczyniecka Method for determination of pharmacological properties of recombinant proteins
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
WO2015105888A1 (en) * 2014-01-07 2015-07-16 Bioatla, Llc Proteins targeting orthologs
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CA2947605A1 (en) * 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
CA2954066A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
RU2764074C2 (ru) * 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CA2977687C (en) 2015-02-24 2024-02-13 Hwai Wen Chang Conditionally active proteins
TWI748962B (zh) * 2015-09-23 2021-12-11 美商建南德克公司 抗vegf抗體之最佳化變異體
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
SI3455261T1 (sl) 2016-05-13 2023-01-31 Bioatla, Inc. Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
PE20200757A1 (es) 2017-07-11 2020-07-27 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
WO1989009284A1 (en) 1988-03-24 1989-10-05 University Of Iowa Research Foundation Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
PT672145E (pt) 1992-11-24 2003-08-29 Searle & Co Polipeptideos de interleucina-3(il-3) com multiplas mutacoes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
BR0207267A (pt) 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2005003345A2 (en) * 2003-06-27 2005-01-13 R. Crea & Co. Look-through mutagenesis
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP1943332A4 (en) * 2005-10-14 2011-04-13 Medimmune Inc CELLULAR DISPLAY OF ANTIBODY LIBRARIES
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
CA2704494A1 (en) 2007-11-02 2009-05-14 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
EP3636759B1 (en) 2009-07-17 2023-10-11 BioAtla, Inc. Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
EP2907873A1 (en) 2015-08-19
US20180371452A1 (en) 2018-12-27
HK1210623A1 (zh) 2016-04-29
JP2015211672A (ja) 2015-11-26
EP2454376B1 (en) 2015-12-02
EP3042957A1 (en) 2016-07-13
AU2010273974A1 (en) 2012-02-09
AU2017203243A1 (en) 2017-06-08
IN2012DN00737A (da) 2015-06-19
CA3034484A1 (en) 2011-01-20
SG10201700096VA (en) 2017-02-27
AU2019203813B2 (en) 2021-03-11
US10920216B2 (en) 2021-02-16
US10106788B2 (en) 2018-10-23
US11976381B2 (en) 2024-05-07
EP3042957B1 (en) 2017-09-13
EP2454376A4 (en) 2013-07-10
EP3636759B1 (en) 2023-10-11
KR20190017070A (ko) 2019-02-19
EP2907873B1 (en) 2016-04-06
EP3406717A1 (en) 2018-11-28
PT3042957T (pt) 2017-12-21
AU2015243076B2 (en) 2017-02-23
WO2011009058A2 (en) 2011-01-20
DK3156485T3 (da) 2019-01-07
AU2010273974A8 (en) 2012-02-23
JP2017205110A (ja) 2017-11-24
AU2017203243B2 (en) 2019-07-11
ES2652340T3 (es) 2018-02-01
EP3156485B1 (en) 2018-09-12
US20210207129A1 (en) 2021-07-08
BR112012001171B1 (pt) 2021-09-21
KR101823872B1 (ko) 2018-01-31
JP6193570B2 (ja) 2017-09-13
US20150024944A1 (en) 2015-01-22
AU2010273974B2 (en) 2016-01-14
SG177687A1 (en) 2012-02-28
US20120165201A1 (en) 2012-06-28
MY160472A (en) 2017-03-15
WO2011009058A3 (en) 2011-04-14
MX2012000803A (es) 2012-06-01
US10047357B2 (en) 2018-08-14
SG10201505075TA (en) 2015-07-30
CA2768247A1 (en) 2011-01-20
KR20120069664A (ko) 2012-06-28
US8859467B2 (en) 2014-10-14
AU2021203220B2 (en) 2023-05-04
CN107090031A (zh) 2017-08-25
EP3636759A1 (en) 2020-04-15
AU2015243076A1 (en) 2015-11-05
JP2012533307A (ja) 2012-12-27
BR112012001171A2 (pt) 2017-06-13
BR122015012748A2 (pt) 2020-01-07
CA2768247C (en) 2019-04-09
JP6681131B2 (ja) 2020-04-15
AU2021203220A1 (en) 2021-06-10
KR20220002712A (ko) 2022-01-06
MX347654B (es) 2017-05-05
EP2454376A2 (en) 2012-05-23
HUE029328T2 (en) 2017-02-28
CN102625848A (zh) 2012-08-01
KR20210013294A (ko) 2021-02-03
PL3042957T3 (pl) 2018-03-30
MY173037A (en) 2019-12-20
ES2701931T3 (es) 2019-02-26
ES2581318T3 (es) 2016-09-05
EP3406717B1 (en) 2019-12-11
DK2907873T3 (da) 2016-06-13
AU2019203813A1 (en) 2019-06-20
KR20180010347A (ko) 2018-01-30
PL2907873T3 (pl) 2016-10-31
US20120245036A1 (en) 2012-09-27
JP6193913B2 (ja) 2017-09-06
DK3042957T3 (da) 2018-01-02
DK3636759T3 (da) 2023-10-23
EP3156485A1 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
DK3406717T3 (da) Samtidig, integreret udvælgelse og udvikling af antistof/protein- performance og ekspression hos produktionsværter
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
BRPI0809677A2 (pt) Anticorpos anti-ige
SMT201700083B (it) Anticorpi monoclonali
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK3118221T3 (da) Proteiner
DK2046826T3 (da) Exendin-fusionsproteiner
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI1011005A2 (pt) anticorpos anti-epcam
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0907237A2 (pt) Anticorpo anti-cldn6
DK2234600T3 (da) Antistofformulering
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
ATE483732T1 (de) Madcam-antikörper
DK2126093T3 (da) Forbedring af proteinfremstilling
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
BRPI0814971A2 (pt) Proteína
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf